- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05203458
Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (HER2 PATH)
HER2 Retrospective Epidemiology Study Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (HER2 PATH)
Study Overview
Status
Conditions
Detailed Description
This is a multicenter, retrospective study to estimate the prevalence of different HER2 expression levels (HER2+, HER2-low, HER2 Ø) in approximately 200 breast cancer patients at FUSCC through the year of 2015 and 3000 breast cancer patients from about 10 medical centres in China between July 2021 and July 2022.
This study will be divided into two parts: The first part will include 200 subjects who were pathologically diagnosed with breast cancer at FUSCC between Jan 2015 and Dec 2015 (PART 1).This part will collect rescored HER2 expression level results based on the archived HER2 IHC slides and re-staining and re-scoring HER-2 IHC while relative demographic, treatment, and clinicopathologic data will be extracted from the FUSCC Breast Cancer Single Disease Database.
The second part will include 3000 patients from all sites in China who were pathologically diagnosed with breast cancer between July 2021 and July 2022 (PART 2). This part will collect re-assessed HER2 expression level results based on the archived HER2 IHC slides. The general information of patients, diagnosis, clinicopathological information were collected from medical records, Hospital Information System (HIS) and Laboratory Information Management System (LIS).
In PART 2, among 3000 patients, 270 from all participating sites except FUSCC should have enough tumor tissue for re-staining and re-scoring HER-2 IHC at FUSCC to analyse the concordance between leading site and other centers.
In PART 2, among 3000 patients, 800 HER-2 IHC samples will be selected for the validation through AI-assisted HER2 assessment system
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Guangzhou, China
- Research Site
-
Jinan, China
- Research Site
-
Shenyang, China
- Research Site
-
Wuhan, China
- Research Site
-
Xi'an, China
- Research Site
-
Zhengzhou, China
- Research Site
-
-
Shanhai
-
Shanghai, Shanhai, China
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients fulfilling all of the following criteria will be eligible for this study:
- Male and female patients must have a histological confirmed diagnosis of BC
- The patients must be ≥18 years old at the diagnosis.
- In PART 1, all patients should be diagnosed at FUSCC between Jan 2015 and Dec 2015.
- In PART 2, all patients should be diagnosed at all participating sites between July 2021 and July 2022.
- Provision of at least 1 archived HER2 IHC slides associated with confirmed diagnosis of BC, which are in good condition for rescoring.
- FISH result is available for HER2 IHC2+ in primary scoring.
Exclusion Criteria:
Patients who meet any of the following criteria will be disqualified from entering the study:
- Absence of all demographic, histopathologic, clinicopathologic information .
- Have a history of other malignancies, other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Prevalence of different HER2 expression levels
Time Frame: Within one year
|
To estimate the prevalence of different HER2 expression levels (HER2+, HER2-low(defined as IHC 1+,2+/ISH-), HER2 Ø) in Chinese breast cancer patients in PART 2.
|
Within one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor size of histopathological
Time Frame: Within one year
|
Tumor size of Histopathological characteristic by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
Positive lymph node number of the histopathological
Time Frame: Within one year
|
Positive lymph node number of histopathological characteristic by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
TNM stage by different HER2 expression levels
Time Frame: Within one year
|
TNM stage by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
Pathological type of histopathological
Time Frame: Within one year
|
Pathological type by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
Histological grade of histopathological
Time Frame: Within one year
|
Histological grade by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
Multi-focal of histopathological
Time Frame: Within one year
|
Multi-focal by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
ER status of histopathological
Time Frame: Within one year
|
ER status by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
ER percentage by different HER2 expression levels.
Time Frame: Within one year
|
ER percentage by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
PR status of histopathological
Time Frame: Within one year
|
PR status by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
PR percentage by different HER2 expression levels.
Time Frame: Within one year
|
PR(Progesterone Receptor) percentage by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
Ki-67 percentage by different HER2 expression levels.
Time Frame: Within one year
|
Histopathological and clinicopathological characteristics by different HER2 expression level (Ø /Low/High) including: Ki-67 percentage,in PART 1 and PART 2
|
Within one year
|
HER2 IHC score of histopathological
Time Frame: Within one year
|
HER2 IHC score by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
FISH status of histopathological
Time Frame: Within one year
|
FISH status by different HER2 expression level (Ø /Low/High) in PART 1 and PART 2
|
Within one year
|
The concordance between historical scoring and reassess scoring in each IHC score category (IHC score Ø, 1+, 2+and 3+)
Time Frame: Within one year
|
To estimate the concordance between historical scoring and reassess scoring in each IHC score category (IHC score Ø, 1+, 2+and 3+) in PART 2
|
Within one year
|
The concordance of HER2 expression between manual and AI assisted HER2 interpretation
Time Frame: Within one year
|
To estimate the concordance of HER2 expression between manual and AI assisted HER2 interpretation among 800 patients in PART 2
|
Within one year
|
The concordance of HER2 expression between leading site (FUSCC) and other centers
Time Frame: Within one year
|
To estimate the concordance of HER2 expression between leading site (FUSCC) and other centers among 270 patients in PART 2
|
Within one year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The prevalence of HER2 IHC0 and HER2 IHC >0<1+
Time Frame: Within one year
|
To estimate the prevalence of HER2 IHC0 and HER2 IHC >0<1+ in PART 2
|
Within one year
|
Age at diagnosis of patients' demographic at baseline
Time Frame: At baseline
|
Age at diagnosis of patients' demographic at baseline by different HER2 expression level in PART 1
|
At baseline
|
BMI of patients' demographic at baseline
Time Frame: At baseline
|
BMI of patients' demographic at baseline by different HER2 expression level in PART 1
|
At baseline
|
Menopause or not of patients' demographic at baseline
Time Frame: At baseline
|
Menopause or not of patients' demographic at baseline by different HER2 expression level in PART 1
|
At baseline
|
The baseline treatment patterns across patients with different HER2 expression levels
Time Frame: At baseline
|
Patients' treatment patterns at baseline, by different HER2 expression level in PART 1
|
At baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wentao Yang, Dr., Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D9673R00011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer, HER2
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Daiichi SankyoCompletedHER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast CancerUnited States
-
AstraZenecaDaiichi SankyoNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerCanada
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States